A Randomized Placebo-Controlled Dose-Response Trial of Muvz™ for Knee and Low-Back Support in Physically Active Adults
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s486836 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Douglas Kalman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Dr. Kiran c Patel College of Osteopathic Medicine, Nova Southeastern University, Ft, Lauderdale, Florida, USA. Hauptthemen laut MEDLINE: Knee Joint, Low Back Pain. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
The current study aimed to investigate the dose-response efficacy and safety of MuvzTM (E-PR-01, a blend of V. negundo and Z. officinale) in 400 mg (High-dose [HD]) and 200 mg (Low-dose [LD]) of daily dose in physically active adults in 90 days. Patients and Methods: The study included 157 adults aged 40-60 having knee/low back joint discomfort. The primary outcome was an enhancement in the overall musculoskeletal health in 90 days. Secondary outcomes included assessing the joint discomfort following physical activity, range of motion, quality of life, and the consumption of rescue medication.
Results
E-PR-01 notably enhanced musculoskeletal health in a dose-dependent manner compared to placebo within 30 days (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nutrition, Dr. Kiran c Patel College of Osteopathic Medicine, Nova Southeastern University, Ft, Lauderdale, Florida, USA.
- Clinical Development Department, Vedic Lifesciences Pvt. Ltd., Mumbai, Maharashtra, India.
- Life Care Hospital, Nashik, Maharashtra, India.
- Sankalp Hospital, Nashik, Maharashtra, India.
- Sparsh Superspeciality Hospital, Panvel, Maharashtra, India.
- Proactive Orthopedic Clinic, Mumbai, Maharashtra, India.
ORCID-Profile: Douglas Kalman, Shalini Srivastava
Zitieren
APA
Kalman, D., Srivastava, S., Desale, A., Chatte, M. D., Nalavade, R. J., Shah, K. M., Karvir, S., & Bhasale, S. (2025). A Randomized Placebo-Controlled Dose-Response Trial of Muvz™ for Knee and Low-Back Support in Physically Active Adults. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s486836
Vancouver
Kalman D, Srivastava S, Desale A, Chatte MD, Nalavade RJ, Shah KM, et al. A Randomized Placebo-Controlled Dose-Response Trial of Muvz™ for Knee and Low-Back Support in Physically Active Adults. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s486836
BibTeX
@article{Kalman2025,
author = {Kalman, Douglas and Srivastava, Shalini and Desale, Ajinkya and Chatte, Manish Devidas and Nalavade, Rohit J and Shah, Kshitij Manoj and Karvir, Sagar and Bhasale, Surendra},
title = {A Randomized Placebo-Controlled Dose-Response Trial of Muvz™ for Knee and Low-Back Support in Physically Active Adults},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s486836}
}
EUVIMED